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Abstract
Background: According to the WHO, osteoporosis is one of the most important non- communicable diseases
worldwide. Different screening procedures are controversially discussed, especially concerning the concomitant
issues of overdiagnosis and harm caused by inappropriate Dual X-ray Absorptiometry (DXA). The aim of this study
was to evaluate the frequency and appropriateness of DXA as screening measure in Switzerland considering
individual risk factors and to evaluate covariates independently associated with potentially inappropriate DXA
screening.
Methods: Retrospective cross-sectional study using insurance claim data of 2013. Among all patients with DXA
screening, women < 65 and men < 70 years without osteoporosis or risk factors for osteoporosis were defined as
receiving potentially inappropriate DXA. Statistics included descriptive measures and multivariable regressions to
estimate associations of relevant covariates with potentially inappropriate DXA screening.
Results: Of 1,131,092 patients, 552,973 were eligible. Among those 2637 of 10,000 (26.4%) underwent potentially
inappropriate DXA screening. Female sex (Odds ratio 6.47, CI 6.41–6.54) and higher age showed the strongest
association with any DXA screening.
Female gender (Odds ratio 1.84, CI 1.49–2.26) and an income among the highest 5% (Odds ratio 1.40, CI 1.01–1.98)
were significantly positively associated with potentially inappropriate DXA screening, number of chronic conditions
(Odds ratio 0.67, CI 0.65–0.70) and living in the central region of Switzerland (Odds ratio 0.67, CI 0.48–0.95)
negatively.
Conclusion: One out of four DXAs for screening purpose is potentially inappropriate. Stakeholders of osteoporosis
screening campaigns should focus on providing more detailed information on appropriateness of DXA screening
indications (e.g. age thresholds) in order to avoid DXA overuse.
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Background
According to the WHO osteoporosis is one of the most im-
portant non-communicable diseases worldwide [1] with a
high burden of disease [2–5]. In Switzerland, one out of
three women at the age of 85 is at risk for an osteoporotic
fracture within ten years [6]. Efficient drugs, which are able
to prevent osteoporotic fractures, are available [7–9]. Thus
identifying patients likely to benefit from such a therapy is
of crucial importance. Besides risk calculators based on in-
dividual behavior characteristics [10, 11], the standard
screening method is Dual X-ray Absorptiometry (DXA)
[12]. Its evidence is controversially discussed at present, es-
pecially concerning the issues of overdiagnosis and harm
resulting from inappropriate DXA screening [13–18]: DXA
as a single procedure does not harm patients directly, as
the amount of radiation applied is almost negligible. Never-
theless harmful effects of radiation can sum up. The real
harm of inappropriate DXA consists in potential additional
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diagnostic procedures (e.g. repeated DXA’s) as well as con-
comitant treatment due to diagnostically significant but
clinically irrelevant DXA results. DXA measurements are
inherently uncertain in relation to fracture risk prediction
[19]. If treatment is initiated based on DXA results alone,
e.g. in asymptomatic persons regardless of risk factors, it is
potentially inappropriate and can cause potentially severe
side effects as well as avoidable costs.
Current knowledge on the use of DXA screening in
Switzerland is scarce. Therefore, the aim of this study
was to evaluate the frequency and appropriateness of
DXA as a screening measure in Switzerland, considering
individual risk factors, and to evaluate covariates inde-
pendently associated with potentially inappropriate DXA
screening.
Methods
Study design and setting
Retrospective cross-sectional analysis using insurance
claims data from the largest insurance company in
Switzerland (Helsana). Data covered in- and outpatient
health care in Switzerland, where all residents are have
mandatory health insurance provided by private health in-
surance companies (details on various insurance models
see below). The study population was extracted from a
dataset of 1,131,092 patients across Switzerland, represent-
ing a sample of approximately 14% of the Swiss population
(see Fig. 1).
Subjects and data collection
Inclusion criteria
All health claims submitted to Helsana for reimburse-
ment of health care provided between January 1st and
December 31st 2013 were considered and included
following codes:
a. Outpatient setting: Outpatient care fees-for-services
positions (Tarmed) and Anatomical Therapeutic
Chemical (ATC) Classification System for drugs.
Fig. 1 Patient inclusion flowchart. This figure shows individual reasons why patients were excluded and the amount of patients finally included in the study
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b. Inpatient setting: Diagnosis Related Groups (DRG),
International Classification of Diseases (ICD) and
Swiss classification of operations (CHOP) for
surgical interventions. An additional file shows this
in more detail [see Additional file 1].
Exclusion criteria
 No data on area of living
 No data on risk factors and treatment of
osteoporosis in 2012
 No data on treatment of osteoporosis in 2014
 Previous use of antiresorptive medication (in this
condition DXA might be used for monitoring of
treatment and not for screening purpose)
 Diagnosis of osteoporosis
 Age below 40 years
Definition of osteoporosis and risk factors for
osteoporosis
Osteoporosis was defined by diagnostic code (ICD,
DRG) or use of antiresorptive medication (ATC). Risk
factors for osteoporosis were defined according to the
FRAX® score [11] and according to recommendations of
the Swiss Association against Osteoporosis (SVGO) [20]
(Table 1).
An additional file shows this in more detail [see
Additional file 1].
Variables
Socio-demographic characteristics
 Age
 Gender
 Chronic conditions: According to the
pharmaceutical cost group (PCG) model by Huber
et al. [21]. We additionally defined a minimum of
three prescriptions per year as precondition for the
following chronic conditions: acid related disorders,
pain, psychological disorders (sleep disorder,
depression) and rheumatological conditions.
 Area of living: Typology of Swiss communities
defined by the Swiss Federal Statistical Office into
‘urban’ (‘central city’, ‘isolated city’, ‘agglomeration’),
and ‘rural’ (‘rural areas’) (data originates from
“Gemeindetypologie - Bundesamt für Statistik” 2003)
 Density of DXA facilities: The number of DXA
facilities per canton was adjusted to the number of
residents per canton and then categorized into four
quartiles (data originates from “Bewilligungstatistik -
Bundesamt für Gesundheit” 2016)
Socio-economic characteristics
 Socio-economic status using income levels per
corresponding zip code as a proxy [22]. Income
level categorized into lowest 5%, middle 90%, and
highest 5%.
 Insurance Status:
 Supplementary private hospital insurance
 Deductibles ≥ or < 1000 Swiss francs (CHF); High
deductible class, e.g. 1000, 1500, 2000, or 2500
CHF as compared to the standard deductible of
300 or 500 CHF
 Managed care: We defined health plans with
capitation, family doctor models, or telemedicine
models as managed care models.
Analysis
First we calculated number and proportion of patients
receiving any DXA screening. In a second step, number
and proportion of patients receiving potentially inappro-
priate respectively appropriate DXA screening were
calculated.
Table 1 Definitions of osteoporosis and risk factors of osteoporosis
Characteristics Coding System Indicator
Osteoporosis a Using ICD, ATC codes Diagnostic code (ICD, DRG), antiresorptive
medication (ATC)
Risk factors for osteoporosis
according to FRAX® scorea [11]
Using ICD, DRG, CHOP,
Tarmed and ATC codes
Steroid medication, fracture in typical
location (distal radius fracture, proximal
humerus fracture, vertebral fracture, femur
fracture) rheumatoid arthritis, insulin
dependent diabetes (as a proxy variable
for type I diabetes), osteogenesis imperfecta,
hyperthyroidism, hypogonadism, chronic liver
disease, nicotine and alcohol abuses, malnutrition,
underweight or malabsorption (including gastric
by-pass and inflammatory bowel disease)
Risk factors for osteoporosis
according to Swiss Association
against Osteoporosis (SVGO) a
Using ICD, DRG, CHOP,
Tarmed and ATC codes
Hyperparathyroidism, hypothyroidism, asthma
or COPD, multiple myeloma, antiepileptic
drugs and anti-HIV drugs
Definition of clinical characteristics and medication; a Data 6 months prior to DXA screening were taken into account
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Any DXA screening performed on women < 65 and on
men < 70 years without any risk factors for osteoporosis
was defined as potentially inappropriate. For presenta-
tion of results, data was categorized by 5-year age strata,
gender and existence of risk factors.
DXA screening performed on women > 65 and on
men > 70 years or DXA screening performed on women
< 65 and on men < 70 years with risk factors for osteo-
porosis was defined as appropriate DXA screening. For
presentation, data was categorized by 5-year age strata,
gender and existence of risk factors.
Furthermore, we analyzed independent covariates for
receiving any DXA screening as well as independent co-
variates for receiving potentially inappropriate DXA
screening.
We used descriptive statistics to provide a general pro-
file of the study population. For continuous variables, we
used means with standard deviations (SD) or median
and interquartile ranges (IQR), for categorical variables
counts and percentages. We used Kruskal-Wallis, Fisher
exact and Chi-Square tests as applicable to compare the
group with and without any DXA, respectively. We cate-
gorized cases by gender and 5-year strata of age.
We performed multivariable regression analysis to es-
timate the effect of any of the covariates age, gender,
health insurance coverage, region density of DXA facil-
ities, income level, number of chronic conditions, risk
factors and known osteoporosis on the patient’s prob-
ability of having any DXA. In the model for the patient’s
probability of having a potentially inappropriate DXA,
we included the covariates age, gender, health insurance
coverage, region, income level, number of chronic condi-
tions and density of DXA facilities. For these multivari-
able models, we used logistic regression.
Results
From our database consisting of 1,131,092 patients,
552,973 were finally included for analysis (See Fig. 1).
The majority of patients was excluded due to age below
40 years (365,511), missing data on risk factors and
treatment of osteoporosis in 2012 (106,500), as well as
due to missing data on treatment of osteoporosis in
2014 (83,437).
Included patients had a median age of 60 (IQR 22.0)
years, 292,377 (52.9%) were female, 424,875 (76.8%) were
living in urban areas and had a median of 1 (IQR 3.0)
chronic conditions (see Table 2).
Proportion of patients with any DXA screening
10,000 (1.8%) of all patients (552,973) included in this
study received any DXA screening. Median age of pa-
tients with any DXA screening was 66 (IQR 16.0) years,
8884 (88.8%) were female, 8101 (81.0%) lived in urban
areas and had a median of 2 (IQR 3.0) chronic
conditions. The age of patients with any DXA was sig-
nificantly higher than the age of patients with no DXA
(mean age 66.0 compared to 60.0). The proportion of
female sex among patients with any DXA was signifi-
cantly higher compared to those patients with no DXA
(88.8% vs. 52.2%). Also most other covariates differed
significantly between patients with any DXA and pa-
tients without (see Table 2).
Proportion of patients with potentially inappropriate DXA
screening
2637 (26.4%) of patients with DXA (10,000) received a
potentially inappropriate DXA screening. 2378 (90.2%)
were female and 259 (9.8%) were male. By definition,
only patients in the age groups < 65 years in women and
in the age groups < 70 years in men were potentially
affected (see Table 3).
Independent covariates associated with any DXA
screening
The majority of investigated covariates were significantly
(p < 0.002) associated with any DXA screening (see Fig. 2).
Following covariates showed the greatest effect: Female
sex (Odds ratio 6.47, CI 6.41–6.54), age group 70–74
(Odds ratio 6.23, CI 6.08–6.38), age group 65–69 (Odds
ratio 6.19, CI 6.04–6.34), age group 75–79 (Odds ratio
5.18, CI 5.03–5.34), age group 55–59 (Odds ratio 5.04, CI
4.89–5.19) as well as the risk factors hypogonadism (Odds
ratio 6.12, CI 6.02–6.22), history of fracture (Odds ratio
4.78, CI 4.62–4.94) and rheumatoid arthritis (Odds ratio
3.24, CI 3.13–3.35). Details see Fig. 2 and Additional file 2.
Independent covariates associated with potentially
inappropriate DXA screening
Female sex (Odds ratio 1.84, CI 1.49–2.26), income level
among the highest 5% (Odds ratio 1.40, CI 1.01–1.98), num-
ber of chronic conditions (Odds ratio 0.67, CI 0.65–0.70)
and living in the central region of Switzerland (Odds ratio
0.67, CI 0.48–0.95) were significantly (p < 0.05) associated
with potentially inappropriate DXA screening. All other
covariates were not significantly associated (Details see Fig. 3
and Additional file 3).
Discussion
In this cross-sectional study, 2637 patients (26.4% of all
10,000 patients with any DXA screening) received a
potentially inappropriate DXA. Female gender and in-
come level among the highest 5%, were significantly
positively associated with potentially inappropriate DXA
screening, number of chronic conditions and living in
the central region of Switzerland negatively.
Overall 10,000 patients (1.8% of our total study popu-
lation) received any DXA screening, 8884 (3.0%) of all
women and 1116 (0.4%) of all men in 2013. Previous
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Table 2 Demographic baseline data
Covariates Total No DXA Any DXA p-Value Test
n 552,973 542,973 (98.2%) 10,000 (1.8%)
Age 60.0 (22.0) 60.0 (21.0) 66.0 (16.0) < 2.2e-16 *** ‘
Female sex 292,377 (52.9%) 283,493 (52.2%) 8884 (88.8%) < 2.2e-16 *** “
Managed care 249,826 (45.2%) 245,628 (45.2%) 4198 (42.0%) 8.52e-11
***
“
Deductible ≥ CHF 1000 143,295 (25.9%) 142,212 (26.2%) 1083 (10.8%) < 2.2e-16 *** “
Supplementary hospital insurance 127,080 (23.0%) 123,689 (22.8%) 3391 (33.9%) < 2.2e-16 *** “
Region < 2.2e-16 *** ““
Midland 110,347 (20.0%) 108,473 (20.0%) 1874 (18.7%)
Northwest 76,568 (13.8%) 75,141 (13.8%) 1427 (14.3%)
East 78,285 (14.2%) 76,914 (14.2%) 1371 (13.7%)
Lake Geneva 70,177 (12.7%) 68,800 (12.7%) 1377 (13.8%)
Ticino 40,729 (7.4%) 39,915 (7.4%) 814 (8.1%)
Central 48,871 (8.8%) 48,225 (8.9%) 646 (6.5%)
Zurich 127,996 (23.1%) 125,505 (23.1%) 2491 (24.9%)
Urban area 424,875 (76.8%) 416,774 (76.8%) 8101 (81.0%) < 2.2e-16
***
“
Density DXA facilities 3.18e-13 *** ““
1. quartile 146,876 (26.6%) 144,549 (26.6%) 2327 (23.3%)
2. quartile 158,878 (28.7%) 155,932 (28.7%) 2946 (29.5%)
3. quartile 156,620 (28.3%) 153,514 (28.3%) 3106 (31.1%)
4. quartile 90,599 (16.4%) 88,978 (16.4%) 1621 (16.2%)
Purchasing power 3.39e-07 *** ““
middle 498,052 (90.1%) 489,136 (90.1%) 8916 (89.2%)
lowest 28,221 (5.1%) 27,744 (5.1%) 477 (4.8%)
highest 26,700 (4.8%) 26,093 (4.8%) 607 (6.1%)
Use of antidepressive drugs 59,602 (10.8%) 57,984 (10.7%) 1618 (16.2%) < 2.2e-16 *** “
Risk factor: History of fracture 1874 (0.3%) 1673 (0.3%) 201 (2.0%) < 2.2e-16 *** “
Risk factor: Osteogenesis imperfecta 1 (0.0%) 1 (0.0%) 0 (0.0%) 1 “
Risk factor: Hypogonadism 3562 (0.6%) 2989 (0.6%) 573 (5.7%) < 2.2e-16 *** “
Risk factor (SVGO): Hyperparathyroidism 341 (0.1%) 317 (0.1%) 24 (0.2%) 2.53e-08 *** “
Risk factor: Hyperthyroidism 1171 (0.2%) 1136 (0.2%) 35 (0.4%) 0.005611 ** “
Risk factor (SVGO): Hypothyroidism 25,595 (4.6%) 24,621 (4.5%) 974 (9.7%) < 2.2e-16 *** “
Risk factor: Malnutrition 2270 (0.4%) 2207 (0.4%) 63 (0.6%) 0.001148 ** “
Risk factor: Steroid therapy 45,443 (8.2%) 43,206 (8.0%) 2237 (22.4%) < 2.2e-16 *** “
Risk factor: Inflammatory bowel disease 4291 (0.8%) 3990 (0.7%) 301 (3.0%) < 2.2e-16 *** “
Risk factor: Rheumatoid arthritis 4900 (0.9%) 4401 (0.8%) 499 (5.0%) < 2.2e-16 *** “
Risk factor: Insulin dependent diabetes 11,399 (2.1%) 11,210 (2.1%) 189 (1.9%) 0.241 “
Risk factor: Chronic liver disease 507 (0.1%) 489 (0.1%) 18 (0.2%) 0.006869 ** “
Risk factor: Nicotine abuse 893 (0.2%) 871 (0.2%) 22 (0.2%) 0.1641 “
Risk factor: Alcohol abuse 1435 (0.3%) 1400 (0.3%) 35 (0.4%) 0.07417 “
Risk factor (SVGO): Emerging risk factors 38,633 (7.0%) 37,539 (6.9%) 1094 (10.9%) < 2.2e-16 *** “
Number of chronic conditions 1.0 (3.0) 1.0 (3.0) 2.0 (3.0) < 2.2e-16 *** ‘
Number and proportion of covariates of patients with any DXA screening and with no DXA screening respectively. Abbreviations: “Total” = all included patients,
“Any DXA” = all patients who received any DXA screening, “No DXA” = all patients receiving no DXA screening. Significance levels are marked accordingly: *** ≤
0.001, ** = 0.001–0.01, * = 0.01–0.05, empty = 0.05–1. ‘= Kruskal-Wallis test, “= Fisher exact test, ““= Chi-Square test
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studies found higher proportions of patients with any
DXA, e.g. 20% for women and 3 to 4% for men [13, 23,
24]. Comparisons between these studies seem difficult
due to differences in populations, settings and time pe-
riods. Female gender, age and the majority of established
risk factors for osteoporosis were significantly associated
with any DXA screening, corresponding with the
literature [13, 18, 23, 25, 26]. This finding confirms that
the set of covariates chosen in our study is valid for dis-
criminating between patients at risk for osteoporosis and
patients not at risk.
In contrast to our finding that 26.8% of all women and
23.2% of all men received a potentially inappropriate DXA,
previous studies reported 10 to 20% of inappropriate DXA
Table 3 Appropriateness of DXA
Men Women
n of patients with
DXA without risk
factor
n of patients with
DXA with≥ 1 risk
factor
N of patients
in the sample
n of patients with
DXA without risk
factor
n of patients with
DXA with≥ 1 risk
factor
N of patients
in the sample
40–44 16 24 32,081 95 70 31,480
45–49 27 50 35,421 206 168 34,998
50–54 39 67 34,311 471 296 34,558
55–59 40 85 31,922 715 443 32,743
60–64 62 70 30,005 891 548 32,141
65–69 75 109 29,949 919 652 32,112
70–74 78 103 24,421 774 651 28,148
75–79 44 85 18,927 534 530 24,150
80–84 44 58 13,477 327 313 20,360
85–89 19 15 7124 120 122 13,878
≥ 90 2 4 2958 19 20 7809
Sum 446 670 260,596 5071 3813 292,377
Number of patients with potentially inappropriate respectively appropriate DXA screening stratified by 5-year strata of age and sex
Fig. 2 Multivariable model of any DXA. Multivariable analysis of socio-demographic, socio-economic and clinical covariates of patients receiving any DXA
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among women and 16% among men [16]. Frost et al. found
that one out of three patients with DXA did not have any
risk factor for osteoporosis, while one out of five patients
with DXA did not have any risk factor when family history
and falls are included [18].
The number of potentially inappropriate DXA increased
continuously until the age of 65 years (e.g. almost doubling
with the age of 60–65 compared to 50–55). Female gender
and a higher age are the two risk factors best known to pa-
tients [27]. This specific subgroup might ask more actively
for DXA screening due to their higher risk awareness. This
might be a result of public campaigns successfully fostering
awareness of osteoporosis among this specific subgroup, at
least in high-income countries like Switzerland [28]. Unfor-
tunately, most public campaigns fail to provide information
on inappropriate DXA screening indications (e.g. younger
age). Gender differences in screening programs in general,
as well as in osteoporosis screening programs, have been
observed before [29–35]. Besides inherent gender differ-
ences, lack of campaigns promoting health specifically for
men might be a major contributor to this finding [36, 37].
Amarnath et al. argue that some physicians still use DXA
as a screening tool for all menopausal women regardless of
age or other risk factors [13].
An income level among the highest 5% was significantly
associated with inappropriate DXA screening as well. A
higher level of income might be a proxy for higher
education [25]. Health campaigns usually reach higher
educated people rather than lower educated, leading to a
higher risk awareness and resulting in higher demand for
screening among this subgroup. Amarnath et al. found
underuse of other screening procedures in patients with
lower education level, confirming our finding [13].
The number of chronic conditions commonly used as a
proxy for an elderly, multimorbid population was signifi-
cantly negatively associated with a potentially inappropri-
ate DXA screening. As multimorbidity is associated with
age and frailty, this population is more prone to osteopor-
osis, and thus more frequently and more appropriately
transferred to DXA screening.
Variations between regions might be due to differences in
needs and attitudes of patients or physicians living in these
regions. Furthermore, differences in physician density and
therefore unequal access to medical supply could be an add-
itional reason. Born et al. reported similar findings for the
central and Lake Geneva region of Switzerland as well [25].
Living in a canton with a higher density of DXA
facilities led to a higher proportion of any DXA screen-
ing. Rubin et al similarly reported a higher density of
DXA facilities as a trigger for a higher use of DXA [16].
This findings undermined the economic model that
higher supply is likely to trigger higher demand [38].
Remarkably, there was no significant association be-
tween a higher density of DXA facilities and potentially
Fig. 3 Multivariable model of potentially inappropriate DXA. Multivariable analysis of age, gender, socio-demographic, socio-economic and clinical
covariates of patients receiving a potentially inappropriate DXA
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inappropriate DXA, therefore not directly contributing
to overuse.
We found a significant positive association with a de-
ductible ≥1000CHF and supplementary hospital insur-
ance with any DXA. However, there was no significant
association of these covariates with potentially inappro-
priate DXA. As discussed above a supplementary hos-
pital insurance is a possible proxy for a higher income
level and thus a higher education leading to a higher de-
mand for DXA screening [25, 39].
Finally, overuse of DXA may be triggered by physi-
cians’ and patients’ belief that the potential benefit of
DXA is weighing out its minimal risk of harm, even in
the absence of risk factors for osteoporosis, regardless of
the risk of overdiagnosis and overtreatment [13, 40, 41].
Strengths
A major strength of this study is the large and representa-
tive sample size (14% of the Swiss population). Many stud-
ies investigating proportions and covariates of DXA
screening were based on smaller samples [16, 18, 25, 42].
We focused on DXA for screening intentions only, while
most studies did not differentiate between reasons for per-
forming DXA (screening, diagnosis, or monitoring of
medical treatment). Hence, we were able to avoid mis-
classification bias concerning the indication for a DXA.
We tested a set of clinically reasonable covariates,
which reasonability was confirmed by the findings of our
regression analysis on covariates.
Limitations
In our database, important risk factors such as family or
patient history were not available (a limitation which a
majority of comparable studies had to face as well).
These circumstances might have led to some misclassifi-
cation bias. Frost et al. reported that 10.3% and 15.1% of
all patients receiving a DXA had a family history of hip
fracture and family history of osteoporosis respectively.
The use of data of 1 year (2013) only restricts the
comparability to other studies and is therefore a
limitation.
Further research and recommendations
Attitudes and beliefs concerning DXA screening among
healthcare providers as well as patients might be inter-
esting aspects to explore by qualitative or mixed
methods research. The results of this research might fa-
cilitate implementation of more appropriate DXA
screening.
As discussed above, further initiatives and campaigns
should not only foster awareness, but should also focus
on correct information transfer concerning screening
indication and benefits.
Additionally a two-step screening process consisting of
risk assessment using cost-effective validated tools
followed by DXA could be beneficial [43–46].
Conclusion
One out of four DXAs for screening purpose is poten-
tially inappropriate. Stakeholders of osteoporosis screen-
ing campaigns should focus on providing more detailed
information on appropriateness of DXA screening indi-
cations (e.g. age thresholds) in order to avoid DXA
overuse.
Additional files
Additional file 1: “Definition of variables”. In this file you can see in
detail which coding was used for diagnosis and risk factors. (PDF 76 kb)
Additional file 2: “Multivariable model of any DXA”. In this file we
present the same data as presented in Fig. 2 (multivariable analysis of
socio-demographic, socio-economic and clinical covariates in patients
with any DXA), but in tabular form including estimate (Odds ratio),
confidence intervals and p-value. Significance levels are marked
accordingly: *** ≤ 0.001, ** = 0.001–0.01, * = 0.01–0.05, empty = 0.05–1.
(XLS 31 kb)
Additional file 3: “Multivariable model of potentially inappropriate DXA”.
In this file we present the same data as presented in Fig. 2 (multivariable
analysis of age, sex, socio-demographic, socio-economic and clinical
covariates in patients with a potentially inappropriate DXA), but in tabular
form including estimate (Odds ratio), confidence intervals and p-value.
Significance levels are marked accordingly: ***≤ 0.001, ** = 0.001–0.01,
* = 0.01–0.05, empty = 0.05–1. (XLS 29 kb)
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